What is claimed:

1. An isolated nucleic acid molecule which encodes a RAC3 protein, comprising a nucleotide sequence at least about 70% homologous to a nucleotide sequence of SEQ ID NO:1, or a complement thereof.

- 2. The isolated nucleic acid molecule of claim 1 comprising the coding sequence of SEQ ID NO:1, or a complement thereof.
- 3. The isolated nucleic acid molecule of claim 2, further comprising about nucleotides 1922-2341 of SEO 1D NO:1.
- 4. The isolated nucleic acid molecule of claim 2, further comprising about nucleotides 3136-3622 of SEQ ID NO:1.
- 5. The isolated nucleic acid molecule of claim 1 comprising the nucleotide sequence of SEQ ID NO:1 or a complement thereof.
- 6. The isolated nuclei acid molecule of claim 1, further comprising about nucleotides 1922-2341 and 3136-3622 of SEQ ID NO:1.
 - 7. The isolated nucleic acid molecule of claim 1, having a RAC3 activity.
- 8. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein which comprises an amino acid sequence at least about 70% homologous to the amino acid sequence of SEQ ID NO:2.
- 9. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein which comprises the amino acid sequence of SEQ ID NO:2.
- 10. An isolated nucleic acid molecule encoding a RAC3 protein comprising a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1.
- 11. An isolated nucleic acid molecule at least 500 nucleotides in length which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1.

10

30

W (35

- 5
- 13. An isolated nucleic acid molecule which is antisense to the nucleic acid molecule of claim 1.
 - 14. A vector comprising the nucleic acid molecule of claim 1.
- 10

- 15. The vector of claim 14, which is a recombinant expression vector.
- 16. A host cell containing the vector of claim 15.
- 17. A method for producing RAC3 protein comprising culturing the host cell of claim 16 in a suitable medium until RAC3 protein is produced.
- 18. The method of claim 17, further comprising isolating RAC3 protein from the medium or the host cell.
- 19. A nonhuman transgenic animal which contains cells carrying a transgene encoding RAC3 protein.
- 20. A nonhuman homologous recombinant animal which contains cells having an altered RAC3 gene.
- 21. An isolated RAC3 protein comprising an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:2.
- 30 22. An isolated RAC3 protein which is encoded by a nucleic acid molecule comprising a nucleotide sequence at least about 60% homologous to a nucleotide sequence of SEQ ID NO:1, or a complement thereof.
- 23. An isolated RAC3 protein which is encoded by a nucleic acid molecule comprising a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or the coding region of SEQ ID NO:1.

5

25. An isolated protein comprising an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:2, wherein the protein retains a RAC3 biological activity.

10

26. The isolated protein of claim 25, comprising an amino acid sequence 60% homologous to an amino acid sequence of SEQ ID NO:2.

27. The isolated protein of any of claim 26, comprising at least one RAC3 domain.

28. An isolated protein comprising the amino acid sequence of SEQ ID NO:2.

回15 回车 中间 里 20

A fusion protein comprising a RAC3 polypeptide operatively linked to a 29. non-RAC3 polypeptide.

30. The fusion protein of claim 29, wherein the RAC3 polypeptide comprises a RAC3 domain.

31.

An antibody that specifically binds a RAC3 protein.

32. The antibody of claim 31, which is monoclonal.

The antibody of claim 32, which is labeled with a detectable substance. 33.

30

34. A pharmaceutical composition comprising the protein of claim 27 and a pharmaceutically acceptable carrier.

35

35. A pharmaceutical composition comprising the antibody of claim 31 and a pharmaceutically acceptable carrier.

36. A method for modulating a cell-associated activity comprising contacting a cell with an agent which modulates RAC3 protein activity or RAC3 nucleic acid

expression such that the cell-associated activity is altered relative to the cell-associated activity of the cell in the absence of the agent.

- A method for treating a subject having a disorder characterized by aberrant RAC3 protein activity or nucleic acid expression comprising administering to the subject a RAC3 modulator such that treatment of the subject occurs.
 - 38. A method for detecting the presence of RAC3 activity in a biological sample comprising contacting a biological sample with an agent capable of detecting an indicator of RAC3 activity such that the presence of RAC3 activity is detected in the biological sample.
 - 39. A kit for detecting the presence of RAC3 activity in a biological sample comprising an agent capable of detecting an indicator of RAC3 activity in a biological sample.
 - 40. A diagnostic assay for identifying a genetic alteration in a cell sample, the presence or absence of the genetic alteration characterized by at least one of (i) aberrant modification or mutation of a gene encoding a RAC3 protein, and (ii) misregulation of said gene or (iii) aberrant post-translational modification of a RAC3 protein.
 - 41. A method for identifying a compound that modulates the activity of a RAC3 protein, comprising:
 - a. providing an indicator composition comprising a protein having RAC3 activity;
 - b. contacting the indicator composition with a test compound; and
 - c. determining the effect of the test compound on RAC3 activity in the indicator composition to thereby identify a compound that modulates the activity of a RAC3 protein.

10

addie -

30